Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Cogstate Ltd ( (AU:CGS) ) is now available.
Cogstate Ltd announced its first webinar in the Investor Insights Series, highlighting its partnership with Medidata to drive innovation in Central Nervous System (CNS) research. This collaboration aims to enhance clinical trial outcomes through Medidata’s advanced platform and Cogstate’s expertise in cognitive assessment, benefiting sponsors, researchers, and patients. The series is designed to expand investor engagement and understanding of Cogstate’s role in CNS research, with future webinars focusing on Alzheimer’s breakthroughs and the company’s central position in supporting clinical trials and commercialization.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is a neuroscience technology company focused on optimizing brain health assessments to aid the development of new medicines and provide earlier clinical insights in healthcare. The company offers rapid, reliable, and sensitive computerized cognitive tests and electronic clinical outcome assessment solutions. Cogstate supports clinical trials with quality assurance services and has partnered with Eisai to distribute its assessments in the USA and Asia.
YTD Price Performance: 33.49%
Average Trading Volume: 114,946
Technical Sentiment Signal: Buy
Current Market Cap: A$235.4M
See more insights into CGS stock on TipRanks’ Stock Analysis page.